Poging GOUD - Vrij
We are expanding our footprint in high-growth markets, particularly in Europe and Asia
Express Pharma
|April 2025
Cotecna Group is a leading provider of testing, inspection, and certification services, providing regulatory compliance solutions across various industries, including pharma. Sebastien Dannaud, Global CEO, Cotecna shares insights on the company's expansion plans, innovation, and growth strategies for the pharma sector, in an exclusive interview with Lakshmipriya Nair

Can you elaborate on the Cotecna Group's offerings and how they support pharma companies in meeting global regulatory standards, especially in highly regulated markets?
At Cotecna, we understand the critical importance of regulatory compliance in the pharma industry, particularly in highly regulated markets such as Europe and Asia. Our expertise spans across Good Manufacturing Practices. (GMP), Good Laboratory Practices (GLP), Good Distribution Practices (GDP), as well as regulatory requirements set by major bodies such as the EMA and WHO.
To support pharma companies in navigating these complex regulations, we offer comprehensive testing and auditing services conducted onsite. Our specialised facilities, such as SHIVA Lab and Cotecna Life Sciences in India, provide advanced pharma testing and regulatory support, ensuring that products meet stringent safety and quality standards. Similarly, Neotron Food Pharma Lab in Europe offers specialised pharma and nutra testing, with a particular focus on biopharma solutions.
By fostering strong synergies between India and Neotron, we ensure a harmonised global service offering that provides consistency, reliability, and compliance assurance to pharma clients worldwide.
How does Cotecna differentiate itself from competitors in the pharma testing and certification space? Are there specific strategies or expansion plans targeting high-growth regions like the US, Europe, and emerging markets?
Cotecna stands out due to its strong technical and scientific expertise, combined with its agility, responsiveness, and commitment to tailored solutions. We often describe our approach as "smart, agile, and highly responsive." This mindset allows us to deliver faster turnaround times, customised services, and a client-centric approach that ensures we meet the specific needs of our partners.
Dit verhaal komt uit de April 2025-editie van Express Pharma.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Express Pharma

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size